FDA Inspection 1246415 — Emily A. DiMango, M.D.

Emily A. DiMango, M.D. — FEI 3013753808

The FDA completed an inspection of Emily A. DiMango, M.D. on Aug 13, 2024 in New York, NY. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 1 citation was issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI)
End Date
Aug 13, 2024
Fiscal Year
2024
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
New York, NY (United States)

Additional Details

Clinical Investigator (CI)

Citations

IDCFRDescription
2272721 CFR 312.64(b)Safety Reports - Serious Events